Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CALCIPOTRIOL
Leo Laboratories Limited
D05AX02
CALCIPOTRIOL
50 Microgram
Cutaneous Solution
Product subject to prescription which may not be renewed (A)
Other antipsoriatics for topical use
Authorised
1994-09-08
Page 1 of 4 PACKAGE LEAFLET: INFORMATION FOR THE USER DOVONEX ® 50 MICROGRAMS/ML SCALP SOLUTION calcipotriol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE, BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet, Dovonex ® scalp solution will sometimes be called Dovonex ® . WHAT IS IN THIS LEAFLET: 1. What Dovonex ® is and what it is used for 2. What you need to know before you use Dovonex ® 3. How to use Dovonex ® 4. Possible side effects 5. How to store Dovonex ® 6. Contents of the pack and other information 1. WHAT DOVONEX ® IS AND WHAT IT IS USED FOR Dovonex ® contains the active substance calcipotriol. Dovonex ® belongs to a group of medicines called anti-psoriatics. It is a type of vitamin D. Vitamin D controls how the cells in your skin grow. If the cells in your skin grow too much you may get psoriasis. Psoriasis is a condition where your skin develops raised red patches and silver coloured scaly patches. The scaly patches are dead cells that would normally fall off your skin without you noticing. Dovonex ® works by reducing the amount of cells your skin makes. This means your symptoms will reduce too. You may begin to see an improv Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dovonex 50 micrograms/ml Scalp Solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Calcipotriol 50 micrograms/ml (as the hydrate). Excipient(s) with known effect: Contains propylene glycol. For the full list of excipients, see 6.1 3 PHARMACEUTICAL FORM Scalp solution. A clear, colourless, slightly viscous scalp solution with an odour of menthol. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dovonex Scalp Solution is indicated for the topical treatment of scalp psoriasis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults: Dovonex Scalp Solution should be applied twice daily (morning and evening) to the affected areas. Maximum weekly dose should not exceed 60 ml. When used together with Dovonex Cream or Ointment, the total dose of calcipotriol should not exceed 5 mg in any week. _PAEDIATRIC POPULATION:_ No data are available. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Due to the content of calcipotriol, Dovonex is contraindicated in patients with known disorders of calcium metabolism (see section 4.4). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Effects on calcium metabolism Due to the content of calcipotriol, hypercalcaemia may occur if the maximum weekly dose is exceeded. Serum calcium is normalised when treatment is discontinued. The risk of hypercalcaemia is minimal when the recommendations relevant to calcipotriol are followed. The maximum weekly dose in adults is 100 g of cream or ointment (equivalent to 5 mg of calcipotriol) or 60 ml of scalp solution (equivalent to 3 mg of calcipotriol). When cream, ointment or cutaneous solution are applied together, the total dose of calcipotriol should not exceed 5 mg per week. HEALTH PRODUCTS R Read the complete document